greeksoup/ stocks
Stocks / Foreign companies / BNTX · Biological Products, (No Diagnostic Substances)

BioNTech SE (BNTX)

BioNTech SE files a 20-F with the SEC once a year, in euros. In the year to 31 December 2025 it reported revenue of EUR 2,870 million, up 4.3% on the year before. Its profit attributable to shareholders was EUR -1,136 million, and diluted earnings per share EUR -4.70.

Earnings per share are per ordinary share, in euros. The share that trades in the US can be a depositary share standing for more or fewer ordinary shares, so no price ratio is worked out on this page.

The public record on BNTX

Planned insider sales7 Form 144 notices in twelve months, $428.6 million; latest 3 September 2026
Options tapeput/call 0.6 by open interest on 26 September 2026; the straddle prices a 7.6% move to 16 October 2026
Holders10 of the followed funds hold it; largest FMR LLC; 2 Schedule 13D or 13G filings in twelve months
Congress0 House trades disclosed in six months
Short interest2.3 million shares short, 2.59 days to cover at 15 September 2026

Profit and loss, 9 fiscal years

Year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020*Dec 2019*Dec 2018Dec 2017
Revenue2,8702,7513,81917,31118,97748210912861.6
Cost of sales6425416002,9952,91259.317.413.79.3
Gross profitn/an/an/an/an/an/a91.211452.3
Research and development2,1052,2541,7831,53794964522614385.5
Operating profit-1,405-1,31469012,64315,284-82.4-182-53.9-61.3
Finance costs69.827.423.918.930565.02.00.026.0
Profit before tax-1,051-6781,18612,95415,046-146-179-47.7-85.9
Income tax85.3-12.42563,5204,754-161-0.20.60.0
Profit for the year-1,136-6659309,43410,29215.2-179-48.3-86.0
Profit attributable to shareholders-1,136-6659309,43410,29215.2-179-48.0-85.7

EUR million, from each year's annual report on the SEC's EDGAR, the year linked to its filing, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated. A year marked * shows the figure as the company restated it in a later annual report (Dec 2019, Dec 2020); the first-filed figure is in the CSV. Profit for the year includes the part that belongs to minority shareholders; profit attributable to shareholders is the part EPS is struck on.

Year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020*Dec 2019*Dec 2018Dec 2017
Diluted EPS-4.70-2.773.8337.7739.630.06-0.85n/an/a
Basic EPS-4.70-2.773.8738.7842.180.06-0.85n/an/a

EUR per ordinary share, as filed.

Cash flow

Year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020*Dec 2019*Dec 2018Dec 2017
Cash from operations4562085,37113,577890-13.5-198-58.9-52.6
Purchase of property, plant and equipment17528624932912866.038.629.924.3
Free cash flow281-78.85,12213,248762-79.5-237-88.8-76.9
Dividends paidn/a0.00.04840.00.0n/an/an/a

EUR million. Purchase of property, plant and equipment is the cash line as filed; purchases of intangible assets and acquisitions are not in it. Free cash flow is cash from operations less that purchase, arithmetic on the two filed lines.

Balance sheet at year end

Year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020*Dec 2019*Dec 2018Dec 2017
Total assets21,98922,53023,00623,27915,8312,319798653n/a
Equity attributable to shareholders19,22419,41120,24620,05611,8941,372493266-48.2
Cash and cash equivalents7,6759,76211,66413,8751,6931,210519412172
Lease liabilities23025421721018284.257.650.8n/a
Trade and other receivables9241,4642,1567,14612,382166n/an/an/a
Inventories11128335844050264.111.75.8n/a
Goodwill36838136261.257.853.73.0n/an/a

EUR million, at each fiscal year end. Borrowings is the company's own stated total where it files one; it is never added up from its parts here.

Ratios on the filed lines

Year toDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020*Dec 2019*Dec 2018Dec 2017
Gross marginn/an/an/an/an/an/a84.0%89.3%84.9%
Operating margin-49.0%-47.8%18.1%73.0%80.5%-17.1%-167.1%-42.2%-99.5%
Net margin-39.6%-24.2%24.4%54.5%54.2%3.2%-164.9%-37.6%-139.1%
Free cash flow margin9.8%-2.9%134.1%76.5%4.0%-16.5%-218.3%-69.6%-124.8%
Return on year-end equity-5.9%-3.4%4.6%47.0%86.5%1.1%-36.3%-18.0%n/a
Effective tax raten/an/a21.6%27.2%31.6%n/an/an/an/a

Arithmetic on the filed lines of the same year: margins over revenue, return on equity as profit attributable to shareholders over year-end equity, tax over profit before tax.

Annual reports on EDGAR

FormYear toFiled
20-F/A31 December 202530 July 2026EDGAR
20-F/A31 December 20251 April 2026EDGAR
20-F31 December 202510 March 2026EDGAR
20-F31 December 202410 March 2025EDGAR
20-F31 December 202320 March 2024EDGAR
20-F31 December 202227 March 2023EDGAR
20-F/A31 December 202126 October 2022EDGAR
20-F31 December 202130 March 2022EDGAR
20-F31 December 202030 March 2021EDGAR
20-F31 December 201931 March 2020EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install